These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29755118)

  • 1. Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.
    Adler NR; Wolfe R; McArthur GA; Kelly JW; Haydon A; McLean CA; Mar VJ
    Br J Cancer; 2018 May; 118(10):1289-1295. PubMed ID: 29755118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
    Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of somatic mutational profile in multiple primary melanomas.
    Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node biopsy in thick malignant melanoma: A 16-year single unit experience.
    Hunger RE; Michel A; Seyed Jafari SM; Shafighi M
    Eur J Dermatol; 2015; 25(5):472-6. PubMed ID: 26394835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients.
    Faut M; Wevers KP; van Ginkel RJ; Diercks GF; Hoekstra HJ; Kruijff S; Been LB; van Leeuwen BL
    Ann Surg Oncol; 2017 Jan; 24(1):142-149. PubMed ID: 27646020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report.
    Vachtenheim J; Kodet R; Fischer O; Kolek V; Strizova Z; Ozaniak A; Simonek J; Stolz A; Pozniak J; Kolarik J; Svorcova M; Vachtenheim J; Lischke R
    Diagn Pathol; 2020 Oct; 15(1):132. PubMed ID: 33100226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
    Fairbairn NG; Orfaniotis G; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy.
    Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG
    Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma.
    Erman AB; Collar RM; Griffith KA; Lowe L; Sabel MS; Bichakjian CK; Wong SL; McLean SA; Rees RS; Johnson TM; Bradford CR
    Cancer; 2012 Feb; 118(4):1040-7. PubMed ID: 21773971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 18. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is sentinel lymph node biopsy of therapeutic relevance for melanoma?
    Möhrle M; Schippert W; Rassner G; Garbe C; Breuninger H
    Dermatology; 2004; 209(1):5-13. PubMed ID: 15237261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy.
    Rubinstein JC; Han G; Jackson L; Bulloch K; Ariyan S; Narayan D; Rothberg BG; Han D
    Cancer Med; 2016 Oct; 5(10):2832-2840. PubMed ID: 27671840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.